<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 OR 15(d) of The
Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
July 17, 2012 (July 23, 2012)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>InferX Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE ALIGN="CENTER" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Delaware</TD>
    <TD STYLE="width: 34%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">0-51720</TD>
    <TD STYLE="width: 31%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">54-1614664</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(State of other jurisdiction</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(Commission</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(IRS Employer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">of incorporation)</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">File Number)</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">Identification No.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; text-indent: 0in">46950 Jennings Farm Drive</TD>
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; text-indent: 0in">Suite 290, Sterling, VA</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; text-indent: 0in">20164</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(Address of principal executive offices)</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(Zip Code)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Registrant&rsquo;s telephone number, including area code: (703)
444-6030</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&#168;</FONT>&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Wingdings">&#168;</FONT>
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Item 5.02 Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 17, 2012, Vijay
Suri, President and CEO of the registrant (&quot;InferX&quot;) and a member of its Board of Directors, resigned as President and
CEO and from the Board of InferX. B.K. Gogia, the founder of InferX, remains as Chairman of the Board and has assumed the positions
of Acting President and CEO of InferX. Mr. Gogia intends to form a new management team for InferX.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><B>Item 5.01 Changes
in Control of Registrant</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A change in control
of InferX occurred as a result of a dilutive issuance of shares on December 1, 2010 that was not disclosed to two holders of debentures
issued by InferX, Fourth Street Fund, LP (&quot;FSF&quot;) and Rahul Argade, an employee of InferX. InferX had sold 1,000,000 shares
of common stock in December 2010 to an investor for $0.002 per share. This sale triggered rights under the debentures to convert
debt into common stock at the same price. On December 23, 2009, FSF entered into a Debenture and Warrant Purchase Agreement with
InferX (&ldquo;FSF Purchase Agreement&rdquo;). Pursuant to the FSF Purchase Agreement, InferX issued FSF an 8% Secured Convertible
Debenture for the principal sum of $150,000 (the &ldquo;FSF Debenture&rdquo;). Similarly, on April 19, 2010, Argade entered into
a Debenture and Warrant Purchase Agreement with InferX (&ldquo;Agrade Purchase Agreement&rdquo;) and pursuant to the Argade Purchase
Agreement, InferX issued Argade an 8% Secured Convertible Debenture for the principal sum of $100,000 dated April 19, 2010 (the
&ldquo;Argade Debenture&rdquo;). The FSF Debenture and the Argade Debenture (together &ldquo;the Debentures&rdquo;) have identical
terms regarding the conversion of the debt into InferX common stock. The Debentures were convertible into shares of common stock
at a conversion price equal to $0.20 per share (the &ldquo;Initial Conversion Price&rdquo;). The Debentures also provided that,
in the event InferX sold any common stock or other equity securities at an effective price per share that was lower than the Initial
Conversion Price (a &ldquo;Dilutive Issuance&rdquo;), the Initial Conversion Price for the Debenture holders would be reduced to
the lower price per share charged in connection with the Dilutive Issuance. In addition, the Debentures obligated InferX to provide
to FSF written notice of a Dilutive Issuance (the &ldquo;Dilutive Issuance Notice&rdquo;), which notice was required to include
the issuance price and other pricing terms, within one business day following such an issuance. Regardless of whether InferX sent
the required Dilutive Issuance Notice, the Debentures provided that the Debenture holders would automatically be entitled to receive
the number of common stock at the Base Conversion Price for all conversions done on or the after the occurrence of a Dilutive Issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Without knowledge of
the Dilutive Issuance, FSF sent notices of conversion on January 19, 2011, May 19, 2011 and December 5, 2011. On each occasion,
InferX honored FSF&rsquo;s conversion request but utilized the Initial Conversion Price of $0.20 instead of the Base Conversion
price of $0.002 per share. As a result of InferX&rsquo;s failure to apply the Base Conversion Price to FSF&rsquo;s conversions
on January 19, 2011, May 19, 2011 and December 5, 2011, InferX failed to issue 57,737,870 shares of common stock due to FSF under
the FSF Debenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 17, 2012, Rahul
Argade notified InferX and Vijay Suri that he was converting $20,000 of principal and $21,397 in interest due into InferX common
stock. Applying the Base Conversion Price that resulted from the Dilutive Issuance, InferX should have issued Rahul Argade 20,698,615
shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">FSF has elected to
receive only 22.52% or 13,000,000 of the shares due the Fund and to release InferX from any financial damages incurred.&nbsp; The
Fund has offered to place 77.48% or 44,737,870 of the shares due FSF into escrow for InferX to use to secure the necessary financing,
incentivize additional management talent and make acquisitions.&nbsp; A percentage of the escrowed shares to be mutually agreed
to will be cancelled upon the settlement of&nbsp; outstanding debt and past due salaries, certain intellectual property and patent
enhancement of its current software products, and future financings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="color: Black">Rahul Argade has
elected to receive only 51.68% or 10,698,615 of the shares due to him&nbsp; and to release InferX from any financial damages incurred.&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Immediately prior to
the issuance of the shares of InferX common stock under the Debentures, there are 20,669,453 shares issued and outstanding of which
Vijay Suri owned 9,779,768 shares or 48.9% of the issued and outstanding shares of InferX. Following the conversion of the Debentures
there will be 44,368,068 shares of InferX common stock issued and outstanding. FSF will own 13,250,000 shares directly, excluding
the 44,737,870 escrowed shares discussed above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="vertical-align: top">Date: July 23, 2012</TD>
    <TD COLSPAN="2"><B><FONT STYLE="font-variant: small-caps"><B>InferX
Corporation</B></B></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 50%">&nbsp;</TD>
    <TD STYLE="width: 4%">By:&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 46%">/s/ B.K. Gogia</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-top: #000000 1px solid">B.K. Gogia<BR>Acting President and CEO</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%"></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; margin-top: 0pt; margin-bottom: 6pt"></P>



</P>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "v319289_8k.htm", "description": "FORM 8-K", "secsgml_size_bytes": 18266}]
{"company-data": {"conformed-name": "INFERX CORP", "cik": "0001329548", "assigned-sic": "7370", "irs-number": "541614664", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-51720", "film-number": "12975189"}, "business-address": {"street1": "46950 JENNINGS FARM DR.", "street2": "STE 290", "city": "STERLING,", "state": "VA", "zip": "20164-8679", "phone": "(703) 444-6030"}, "mail-address": {"street1": "46950 JENNINGS FARM DR.", "street2": "STE 290", "city": "STERLING,", "state": "VA", "zip": "20164-8679"}, "former-company": {"former-conformed-name": "BLACK NICKEL ACQUISITION CORP I", "date-changed": "20050608"}}
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
July 17, 2012 (July 23, 2012)
InferX Corporation
(Exact name of registrant as specified in
its charter)
Delaware
0-51720
54-1614664
(State of other jurisdiction
(Commission
(IRS Employer
of incorporation)
File Number)
Identification No.)
46950 Jennings Farm Drive
Suite 290, Sterling, VA
20164
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including area code: (703)
444-6030
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
¨
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On July 17, 2012, Vijay
Suri, President and CEO of the registrant ("InferX") and a member of its Board of Directors, resigned as President and
CEO and from the Board of InferX. B.K. Gogia, the founder of InferX, remains as Chairman of the Board and has assumed the positions
of Acting President and CEO of InferX. Mr. Gogia intends to form a new management team for InferX.
Item 5.01 Changes
in Control of Registrant
A change in control
of InferX occurred as a result of a dilutive issuance of shares on December 1, 2010 that was not disclosed to two holders of debentures
issued by InferX, Fourth Street Fund, LP ("FSF") and Rahul Argade, an employee of InferX. InferX had sold 1,000,000 shares
of common stock in December 2010 to an investor for $0.002 per share. This sale triggered rights under the debentures to convert
debt into common stock at the same price. On December 23, 2009, FSF entered into a Debenture and Warrant Purchase Agreement with
InferX ("FSF Purchase Agreement"). Pursuant to the FSF Purchase Agreement, InferX issued FSF an 8% Secured Convertible
Debenture for the principal sum of $150,000 (the "FSF Debenture"). Similarly, on April 19, 2010, Argade entered into
a Debenture and Warrant Purchase Agreement with InferX ("Agrade Purchase Agreement") and pursuant to the Argade Purchase
Agreement, InferX issued Argade an 8% Secured Convertible Debenture for the principal sum of $100,000 dated April 19, 2010 (the
"Argade Debenture"). The FSF Debenture and the Argade Debenture (together "the Debentures") have identical
terms regarding the conversion of the debt into InferX common stock. The Debentures were convertible into shares of common stock
at a conversion price equal to $0.20 per share (the "Initial Conversion Price"). The Debentures also provided that,
in the event InferX sold any common stock or other equity securities at an effective price per share that was lower than the Initial
Conversion Price (a "Dilutive Issuance"), the Initial Conversion Price for the Debenture holders would be reduced to
the lower price per share charged in connection with the Dilutive Issuance. In addition, the Debentures obligated InferX to provide
to FSF written notice of a Dilutive Issuance (the "Dilutive Issuance Notice"), which notice was required to include
the issuance price and other pricing terms, within one business day following such an issuance. Regardless of whether InferX sent
the required Dilutive Issuance Notice, the Debentures provided that the Debenture holders would automatically be entitled to receive
the number of common stock at the Base Conversion Price for all conversions done on or the after the occurrence of a Dilutive Issuance.
Without knowledge of
the Dilutive Issuance, FSF sent notices of conversion on January 19, 2011, May 19, 2011 and December 5, 2011. On each occasion,
InferX honored FSF's conversion request but utilized the Initial Conversion Price of $0.20 instead of the Base Conversion
price of $0.002 per share. As a result of InferX's failure to apply the Base Conversion Price to FSF's conversions
on January 19, 2011, May 19, 2011 and December 5, 2011, InferX failed to issue 57,737,870 shares of common stock due to FSF under
the FSF Debenture.
On June 17, 2012, Rahul
Argade notified InferX and Vijay Suri that he was converting $20,000 of principal and $21,397 in interest due into InferX common
stock. Applying the Base Conversion Price that resulted from the Dilutive Issuance, InferX should have issued Rahul Argade 20,698,615
shares.
FSF has elected to
receive only 22.52% or 13,000,000 of the shares due the Fund and to release InferX from any financial damages incurred.  The
Fund has offered to place 77.48% or 44,737,870 of the shares due FSF into escrow for InferX to use to secure the necessary financing,
incentivize additional management talent and make acquisitions.  A percentage of the escrowed shares to be mutually agreed
to will be cancelled upon the settlement of  outstanding debt and past due salaries, certain intellectual property and patent
enhancement of its current software products, and future financings.
Rahul Argade has
elected to receive only 51.68% or 10,698,615 of the shares due to him  and to release InferX from any financial damages incurred.
Immediately prior to
the issuance of the shares of InferX common stock under the Debentures, there are 20,669,453 shares issued and outstanding of which
Vijay Suri owned 9,779,768 shares or 48.9% of the issued and outstanding shares of InferX. Following the conversion of the Debentures
there will be 44,368,068 shares of InferX common stock issued and outstanding. FSF will own 13,250,000 shares directly, excluding
the 44,737,870 escrowed shares discussed above.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: July 23, 2012
InferX
Corporation
By:
/s/ B.K. Gogia
B.K. Gogia
Acting President and CEO